SBIR-STTR Award

The World Health Organization estimates that over 350 million people are at risk of developing leishmaniasis and infection prevalence is 14 million people in the world. Annually, 2 million people are infected with Leishmania species and 270,000 will die. Leishmaniasis is one of the most important parasitic diseases affecting the U.S. military today, with over 2500 U.S. military personnel diagnosed with cutaneous leishmaniasis (CL). Current non-immunization based treatments are variably effective, highly toxic, expensive, and there are no vaccines in clinical use. Significant evidence has supported the role of the immune system in controlling Leishmania infection. Thus, a vaccination remains an attractive disease prevention strategy. Two significant scientific knowledge gaps must be addressed: 1) a vaccine that can access the skin resident dendritic cells (DCs), and 2) the identification of Leishmania antigens that are biologically relevant in humans. Needle based vaccines bypass these immunopotent skin cells. The long-term objective of this proposal is to develop a nanoscale polymersome-based vaccine that delivers an antigen and adjuvant to skin dendritic cells through transfollicular immunization (TFI). We will characterize the feasibility of integrating the Toll-like receptor 7/8 agonist resiquimod (RSQ) into the polymersome membrane and encapsulating a model Leishmania antigen, Leishmania homolog of receptors for activated C kinase (LACK), into the aqueous core. We will then evaluate its functional properties in generating a TH1-type cytokine profile and functional cytotoxic CD8+ T cells in vivo. We hypothesize that co-encapsulation of LACK and RSQ into the nanovaccine can be achieved in a stepwise manner and that the resulting nanovaccine will penetrate the follicle and activate skin DCs. We also hypothesize that the topical administration of this nanovaccine will induce a LACK-specific T cell response. Finally, we hypothesize that this nanovaccine will protect against challenge with a visceral Leishmania strain in a hamster model. AIM 1 Construct a nanovaccine encapsulating the antigen LACK and TLR7/8 agonist RSQ (LACK/RSQ-NPS). AIM 2 Determine the optimal physicochemical properties of LACK/RSQ-nanovaccine to penetrate the follicular duct, activate skin DCs, and induce a LACK-specific adaptive immune response. AIM 3 Determine if the LACK/RSQ-nanovaccine induces protective immune responses in vivo. We anticipate the data generated from this proposal will result in a commercially viable topical nanovaccine that can access skin DCs via the transfollicular route. The NIAID supports basic, preclinical, and clinical research on immune-mediated diseases such as leishmaniasis and the development of effective vaccines. The aims proposed in this SBIR Phase I program are consistent with the mission statement of the NIAID.

Public Health Relevance:
The World Health Organization estimates that over 350 million people are at risk of developing leishmaniasis and infection prevalence is 14 million people in the world. Annually, 2 million people are infected with Leishmania species and 270,000 will die. Leishmaniasis is one of the most important parasitic diseases affecting the U.S. military today. We plan to develop a nanovaccine against Leishmania that delivers the vaccine payload through the hair follicle duct to stimulate skin immune cells, all without a needle. This major advance in Leishmania vaccine design may provide the first effective vaccine against Leishmania and would create biotechnology jobs in the US via US military contracts and international government contracts in countries suffering from leishmaniasis.

Thesaurus Terms:
0-11 Years Old;Atgn;Activities Of Daily Living;Activities Of Everyday Life;Address;Adjuvant;Affect;Agonist;Antibodies;Antigens;Area;Armed Forces Personnel;Basic Research;Basic Science;Biotechnology;Bypass;Cd8;Cd8b;Cd8b1;Cd8b1 Gene;Cells;Child;Child Human;Child Youth;Children (0-21);Clinical;Clinical Research;Clinical Study;Communicable Diseases;Conflict;Conflict (Psychology);Contracting Opportunities;Contracts;Country;Cream;Cricetinae;Cutaneous Leishmaniasis;Data;Dendritic Cells;Dendritic Cell Activation;Department Of Defense;Development;Diagnosis;Disease;Disorder;Dose;Drug Formulations;Duct;Duct (Organ) Structure;Encapsulated;Formulation;Genehomolog;Generations;Goals;Government;Hair Follicle;Hair Follicle Structure;Hamsters;Hamsters Mammals;Heating;Homolog;Homologous Gene;Homologue;Human;Immune;Immune Response;Immune System;Immunity;Immunization;Immunologic Sensitization;Immunologic Stimulation;Immunological Sensitization;Immunological Stimulation;Immunostimulation;Infection;Infectious Disease Pathway;Infectious Diseases;Infectious Diseases And Manifestations;Infectious Disorder;Infectious Skin Diseases;International;Jobs;Kala-Azar;Killings;Kinetics;Knowledge;Loinc Axis 2 Property;Loinc Axis 4 System;Lyt3;Lead;Leishmania;Leishmania (Genus);Leishmaniasis;Life;Man (Taxonomy);Mediating;Membrane;Methods;Mice;Mice Mammals;Military;Military Personnel;Mission;Modeling;Modern Man;Monitor;Murine;Mus;Niaid;National Institute Of Allergy And Infectious Disease;Needles;Occupations;Parasites;Parasitic Diseases;Pathway Interactions;Pb Element;Penetration;Phase;Prevalence;Prevention Strategy;Preventive Strategy;Professional Postions;Property;Regimen;Resolution;Risk;Rodent Model;Role;Route;Sbir;Sbirs (R43/44);Skin;Small Business Innovation Research;Small Business Innovation Research Grant;Solubility;System;T Cell Response;T-Cells;T-Lymphocyte;Tlr7;Tlr7 Gene;Tlr7 Receptor;Technology;Testing;Thymus-Dependent Lymphocytes;Toll-Like Receptor 7;Topical Drug Administration;Topical Application;Translating;Vaccination;Vaccine Adjuvant;Vaccine Design;Vaccines;Veiled Cells;Visceral;Visceral Leishmaniasis;World Health Organization;Allergic/Immunologic Body System;Allergic/Immunologic Organ System;Aqueous;Base;Cancer Prevention;Children;Cytokine;Cytotoxic;Daily Living Functionality;Design;Designing;Developmental;Disease Prevention;Disease/Disorder;Disorder Prevention;Functional Ability;Functional Capacity;Htlr7;Heavy Metal Pb;Heavy Metal Lead;Host Response;Human Tlr7 Protein;Human Toll-Like Receptor 7;Immunogen;Immunogenic;Immunoresponse;In Vivo;Membrane Structure;Nano Materials;Nano Meter Scale;Nano Meter Sized;Nano Particle;Nano Scale;Nanomaterials;Nanometer Scale;Nanometer Sized;Nanoparticle;Nanoscale;Novel;Pathway;Pre-Clinical Research;Preclinical Research;Programs;Prophylactic;Protein Kinase C Receptor;Receptors For Activated C Kinase;Resiquimod;Skin Infection;Social Role;Subcutaneous;Thymus Derived Lymphocyte;Topical Administration;Topical Drug Application;Topically Applied;Vaccine Delivery;Youngster

The World Health Organization estimates that over 350 million people are at risk of developing leishmaniasis and infection prevalence is 14 million people in the world. Annually, 2 million people are infected with Leishmania species and 270,000 will die. Leishmaniasis is one of the most important parasitic diseases affecting the U.S. military today, with over 2500 U.S. military personnel diagnosed with cutaneous leishmaniasis (CL). Current non-immunization based treatments are variably effective, highly toxic, expensive, and there are no vaccines in clinical use. Significant evidence has supported the role of the immune system in controlling Leishmania infection. Thus, a vaccination remains an attractive disease prevention strategy. Two significant scientific knowledge gaps must be addressed: 1) a vaccine that can access the skin resident dendritic cells (DCs), and 2) the identification of Leishmania antigens that are biologically relevant in humans. Needle based vaccines bypass these immunopotent skin cells. The long-term objective of this proposal is to develop a nanoscale polymersome-based vaccine that delivers an antigen and adjuvant to skin dendritic cells through transfollicular immunization (TFI). We will characterize the feasibility of integrating the Toll-like receptor 7/8 agonist resiquimod (RSQ) into the polymersome membrane and encapsulating a model Leishmania antigen, Leishmania homolog of receptors for activated C kinase (LACK), into the aqueous core. We will then evaluate its functional properties in generating a TH1-type cytokine profile and functional cytotoxic CD8+ T cells in vivo. We hypothesize that co-encapsulation of LACK and RSQ into the nanovaccine can be achieved in a stepwise manner and that the resulting nanovaccine will penetrate the follicle and activate skin DCs. We also hypothesize that the topical administration of this nanovaccine will induce a LACK-specific T cell response. Finally, we hypothesize that this nanovaccine will protect against challenge with a visceral Leishmania strain in a hamster model. AIM 1 Construct a nanovaccine encapsulating the antigen LACK and TLR7/8 agonist RSQ (LACK/RSQ-NPS). AIM 2 Determine the optimal physicochemical properties of LACK/RSQ-nanovaccine to penetrate the follicular duct, activate skin DCs, and induce a LACK-specific adaptive immune response. AIM 3 Determine if the LACK/RSQ-nanovaccine induces protective immune responses in vivo. We anticipate the data generated from this proposal will result in a commercially viable topical nanovaccine that can access skin DCs via the transfollicular route. The NIAID supports basic, preclinical, and clinical research on immune-mediated diseases such as leishmaniasis and the development of effective vaccines. The aims proposed in this SBIR Phase I program are consistent with the mission statement of the NIAID.